In:
PLOS ONE, Public Library of Science (PLoS), Vol. 15, No. 12 ( 2020-12-31), p. e0244293-
Kurzfassung:
It remains limited whether diabetes mellitus (DM) and hypertension (HTN) affect the prognosis of advanced hepatocellular carcinoma (HCC) treated with sorafenib. Our study attempted to elucidate the roles of DM/HTN and the effects of diabetes medications among advanced HCC patients receiving sorafenib. Methods From August 2012 to February 2018, 733 advanced HCC patients receiving sorafenib were enrolled at China Medical University, Taichung, Taiwan. According to the presence/absence of DM or HTN, they were divided into four groups: control [DM(-)/HTN(-), n = 353], DM-only [DM(+)/HTN(-), n = 91] , HTN-only [DM(-)/HTN(+), n = 184] and DM+HTN groups [DM(+)/HTN(+), n = 105] . Based on the types of diabetes medications, there were three groups among DM patients (the combined cohort of DM-only and DM+HTN groups), including metformin (n = 63), non-metformin oral hypoglycemic agent (OHA) (n = 104) and regular insulin (RI)/neutral protamine hagedorn (NPH) groups (n = 29). We then assessed the survival differences between these groups. Results DM-only and DM+HTN groups significantly presented longer overall survival (OS) than control group (control vs. DM-only, 7.70 vs. 11.83 months, p = 0.003; control vs. DM+HTN, 7.70 vs. 11.43 months, p = 0.008). However, there was no significant OS difference between control and HTN-only group (7.70 vs. 8.80 months, p = 0.111). Besides, all groups of DM patients showed significantly longer OS than control group (control vs. metformin, 7.70 vs. 12.60 months, p = 0.011; control vs. non-metformin OHA, 7.70 vs. 10.80 months, p = 0.016; control vs. RI/NPH, 7.70 vs. 15.20 months, p = 0.026). Conclusions Rather than HTN, DM predicts better prognosis in advanced HCC treated with sorafenib. Besides, metformin, non-metformin OHA and RI/NPH are associated with longer survival among DM-related advanced HCC patients receiving sorafenib.
Materialart:
Online-Ressource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0244293
DOI:
10.1371/journal.pone.0244293.g001
DOI:
10.1371/journal.pone.0244293.g002
DOI:
10.1371/journal.pone.0244293.g003
DOI:
10.1371/journal.pone.0244293.t001
DOI:
10.1371/journal.pone.0244293.t002
DOI:
10.1371/journal.pone.0244293.t003
DOI:
10.1371/journal.pone.0244293.t004
DOI:
10.1371/journal.pone.0244293.t005
DOI:
10.1371/journal.pone.0244293.t006
DOI:
10.1371/journal.pone.0244293.s001
DOI:
10.1371/journal.pone.0244293.s002
DOI:
10.1371/journal.pone.0244293.s003
DOI:
10.1371/journal.pone.0244293.s004
DOI:
10.1371/journal.pone.0244293.s005
DOI:
10.1371/journal.pone.0244293.s006
DOI:
10.1371/journal.pone.0244293.s007
DOI:
10.1371/journal.pone.0244293.r001
DOI:
10.1371/journal.pone.0244293.r002
DOI:
10.1371/journal.pone.0244293.r003
DOI:
10.1371/journal.pone.0244293.r004
Sprache:
Englisch
Verlag:
Public Library of Science (PLoS)
Publikationsdatum:
2020
ZDB Id:
2267670-3
Permalink